CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChinese PLA General Hospital
About this trial
This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms.
Eligibility criteria
Qualifiers
Age 18-75 years,
no gender restrictions;
ECOG score ≤ 2 points;
Expected survival period is not less than 3 months;
Disqualifiers
Severe heart failure with left ventricular ejection fraction <50%;
A history of severe lung function impairment; Combined with other advanced malignant tumors;
Complicated with severe infection that could not be effectively controlled;
Severe autoimmune disease or congenital immune deficiency;
Trial design
Treatments tested in this trial
- CAR19BCMA-T cells
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov